Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: RVMD revmed.com
Revolution Medicines is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers, which represent a large and historically difficult-to-treat segment of solid tumors. The company's pipeline centers on RAS(ON) inhibitors — a class of drugs designed to suppress diverse oncogenic variants of RAS proteins. Its most advanced candidate, daraxonrasib (RMC-6236), is a RAS(ON) multi-selective inhibitor with an NDA under FDA review for previously treated metastatic pancreatic cancer, and is being studied across multiple tumor types and lines of therapy. The pipeline also includes elironrasib (RAS G12C-selective), zoldonrasib (RAS G12D-selective), and RMC-5127 (RAS G12V-selective), all in clinical development across pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Revolution Medicines has no approved products and generates no product revenue; it is funded through equity offerings, convertible notes, and a royalty funding arrangement with Royalty Pharma. The company has established an Expanded Access Program distributing daraxonrasib to over 2,000 patients and is building U.S. and global commercial infrastructure in preparation for a potential launch. Updated
A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants shopping for acquisitions have very specific reasons they cannot afford to stop.
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math…
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental…
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Live Updates Nike Was Downgraded Again8:30am ETWall Street has apparently lost its patience with Nike. After pushing recovery hopes out a bit further with its last batch of earnings, analysts at HSBC…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
Wednesday's top analyst upgrades and downgrades included Broadcom, Clean Energy Fuels, Dish Network, First Republic Bank, Gaming and Leisure Properties, Occidental Petroleum, Revolution Medicines, Veeva Systems and Workday.
Friday's top analyst upgrades and downgrades included AT&T, Exxon Mobil, Hasbro, Juniper Networks, Moderna, Palo Alto Networks, Snap, Teva Pharmaceutical, Under Armour and Zscaler.
Monday's top analyst upgrades, downgrades and initiations included American Express, ADT, Gilead Sciences, Logitech, PACCAR, Regions Financial, Stamps.com and Vivint Smart Home.
Revolution Medicines is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers, which represent a large and historically difficult-to-treat segment of solid tumors.
24/7 Wall St.'s 12-month price target for RVMD is $297.61, rated Buy. The Wall Street consensus target is $258.79. RVMD price prediction →
